A class action lawsuit has been filed against Medtronic, Inc. on behalf of shareholders, alleging that the company made false and misleading statements that failed to disclose their Infuse Bone Graft problems and the extent to which sales of the bone stimulator were dependent on “off-label” uses the company was promoting, which have been associated with a number of serious and life-threatening complications. The plaintiffs allege that the company concealed or failed to disclose the extent to which revenues were dependent on applications of the Infuse Bone Graft that were not approved by the FDA, and which Medtronic had not established as safe or effective. They also indicate that the company failed to disclose that a significant number of patients who received the Medtronic Infuse Bone Graft for an unapproved use, were suffering severe medical complications. | LINK
Related Posts Within Doctor Pundit:
Originating from Saint Paul, Minnesota, [doctorpundit.com] is a weblog about the policy of healthcare and where it intersects with politics and public opinion; it is edited by Michael Douglas, MD, MBA. Welcome, and please consider my take on what is Healthcare 2.0, complemented by a few of my thoughts on my personal avocations and guilty pleasures: music, prose, and writing. Follow Doctor Pundit via RSS above.
RT @hjluks: Reputation Management - A big driver for engaging in healthcare and social media http://t.co/OFaqw04O #hcsm #hcsmca
The role of low-dose aspirin in the prevention of colorectal cancer: Expert Opinion on Therapeutic Targe... http://t.co/lmbq29EZ #pharma
DOCTOR PUNDIT @ ONE YEAR | An occasional DP series from 2010 highlighting healthcare policy trends over the period from 2009-2010 in a compare/contrast format.
